About
Eliaz Therapeutics Inc is a biotechnology and MedTech company founded in 2015 by Dr. Isaac Eliaz, specializing in innovative therapeutic apheresis devices. The company focuses on developing technology to selectively remove Galectin-3 (Gal-3) from the bloodstream, a protein linked to severe inflammatory and fibrotic diseases, immune dysregulation, kidney deterioration, and cancer. The flagship product, the XGal-3® apheresis column, is an FDA Breakthrough Device designed to treat sepsis and sepsis-induced acute kidney injury (AKI). This device aims to improve patient outcomes by targeting Galectin-3, addressing conditions that currently lack effective treatments. Eliaz Therapeutics holds over 60 patents worldwide and has received NIH funding for research and development. The company is supported by global manufacturing partnerships and a leadership team with extensive experience in healthcare and biotech, targeting hospitals and healthcare providers managing critical care patients.
Technologies
Keywords
Company Information
- Employees8
- Founded2015
- Total Funding$2000000
Location
398 Tesconi Ct, Santa Rosa, California, United States, 95401-4653
